5 Top NASDAQ Biotech Stocks: Neovasc Leads the Week

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) continued its newfound gain this week. This past week NBI went up 8.02 percent over the last five trading days and traded at 3,516.09 points. The Index is up 26.81 percent year-to-date.
Last week the Investing News Network (INN) reported on a stock decline to SteadyMed (NASDAQ:STDY) due to a Food and Drug Administration (FDA) denial letter for a trial. This move indicates a potentially stricter regulatory agency when it comes to pharmaceutical candidates. INN also reported on the FDA’s warning letter to US Stem Cell (OTCMKTS:USRM) regarding the safety of their cell-based therapy products and the actual limitations of these.

• Neovasc (NASDAQ:NVCN)
• Adaptimmune Therapeutics plc (NASDAQ:ADAP)
• Curis (NADAQ:CRIS)
• Vericel (NASDAQ:VCEL)
• MannKind (NASDAQ:MNKD)

Neovasc

Neovasc is a specialty medical device company focused on two particular cardiovascular products. Last week the company announced a judgement affirmation from the District Court in Massachusetts, meaning the company has to pay full judgement of approximately of $112 million.
“There are no other monetary damages arising from this award; and Neovasc remains the joint inventor of the ‘964 patent, one of the patents in the Tiara patent family… both parties having freedom to use the patent without an obligation to pay royalties to the other.”
Neovasc gained 42.61 percent last week and closed the week at $1.14 per share.

Adaptimmune Therapeutics plc

Adaptimmune is a company working T-cell therapies to treat cancer. Last week the company announced their second quarter financial results. James Noble, the company’s CEO said the company started their first two trials for MAGE-A4 and AFP.
Adaptimmune Therapeutics gained 26.30 percent last week and closed the week at $6.58 per share.

Curis

Curis is a biotechnology company working on the development of drug candidates for cancer treatments. Last week the company announced the presentation of a poster for a current trial data of the CA-170 Phase 1 clinical trial.
Curis gained 25.15 percent last week and closed the week at $2.09 per share.

Vericel

Vericel is a company developing cell-based therapies for patients. On August 9 the company released their financial report for the second quarter of 2017. However, there haven’t been any other news to cause the stock increase.
Vericel gained 24.29 percent last week and closed the week at $4.35 per share.

MannKind

MannKind is a biopharmaceutical company focused on the development of treatments for patients facing diabetes. Last week the company announced it was going to present new data on their programs at an upcoming conference. However, there haven’t been any other news to cause the stock increase.
MannKind gained 20.65 percent last week and closed the week at $1.87 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

** This article is updated each week. Please scroll to the top for the most recent information**

5 Top NASDAQ Biotech Stocks: Xoma Takes the Week

August 27

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) finally began turning things around from the decrease it had seen for the past few weeks. This past week NBI went up 2.31 percent over the last five trading days and traded at 3,254.95 points. The Index is up 17.39 percent year-to-date.
Last week the Investing News Network (INN) reported on Insys Therapeutics (NASDAQ:INSY) settling a lawsuit with the State of Illinois regarding the damage caused by the damage of their fentanyl-based products in the community. Several other cities and states have filed lawsuits against pharmaceutical companies seeking retribution for the damage their products have had and what many claim have been irregular marketing practices. INN also reported the decline Cardiome Pharma (NASDAQ:CRME; TSX:COM) suffered after the US Food and Drug Administration (FDA) denied, yet again, the approval of Brinavess, a corrective treatment for an arrhythmic heartbeat.

• Xoma (NASDAQ:XOMA)
• Lifevantage (NASDAQ:LFVN)
• AVEO Pharmaceuticals (NASDAQ:AVEO)
• Chiasma (NASDAQ:CHMA)
• Adamis Pharmaceuticals (NASDAQ:ADMP)

Xoma

Xoma is a biotech company engaged on licensing agreements related to antibodies technology. Last week the company announced it licensed to Novartis (NYSE:NVS) the commercial rights of gevokizumab.
Xoma gained 47.61 percent last week and closed the week at $11.10 per share.

Lifevantage

Lifevantage is a novel company working on the development of advanced nutraceutical dietary supplements and skin care products. Last week the company announced it will release their fourth quarter financials alongside the ones for their fiscal 2017 year on September 7.
Lifevantage gained 26.09 percent last week and closed the week at $3.77 per share.

AVEO Pharmaceuticals

AVEO is a biopharmaceutical company working on the development of oncology therapeutics. The company is still riding a gain thanks to their financial results release on August 9.
AVEO Pharmaceuticals gained 23.78 percent last week and closed the week at $3.80 per share.

Chiasma

Chiasma is a biopharmaceutical company focused on rare diseases. On August 10 the company released their financial results for the second quarter of 2017.
Chiasma gained 18.92 percent last week and closed the week at $2.20 per share.

Adamis Pharmaceuticals

Adamis is a specialty biopharmaceutical company focused on the areas of respiratory disease and allergies. On June 15 the company announced the FDA approval of their epinephrine injection. However, there haven’t been any other news to cause the stock increase.
Adamis Pharmaceuticals gained 16.30 percent last week and closed the week at $5.35 per share.
Don’t forget to follow @INN_LifeScience for real-time updates!
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.